+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pertuzumab"

Breast Cancer Drugs Market Size, Share & Trends Analysis Report By Therapy (Targeted, Hormonal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Cancer Type (Hormone Receptor, HER2+), And Segment Forecasts, 2023-2030 - Product Thumbnail Image

Breast Cancer Drugs Market Size, Share & Trends Analysis Report By Therapy (Targeted, Hormonal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Cancer Type (Hormone Receptor, HER2+), And Segment Forecasts, 2023-2030

  • Report
  • June 2023
  • 180 Pages
  • Global
From
HER2 Positive Breast Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

HER2 Positive Breast Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 250 Pages
  • Global
From
HER2-Positive Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2032 - Product Thumbnail Image

HER2-Positive Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2032

  • Report
  • November 2023
  • 276 Pages
  • Global
From
Breast Cancer - Pipeline Insight, 2024 - Product Thumbnail Image

Breast Cancer - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 180 Pages
  • Global
From
Herceptin (Trastuzumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars, Industry/Non-Industry Partnerships - Product Thumbnail Image

Herceptin (Trastuzumab) Biosimilars: Focus on Approved & Launched Biosimilars, Investigational & Research Use Biosimilars, Inactive/Terminated/Withdrawn Biosimilars, Industry/Non-Industry Partnerships

  • Report
  • August 2021
  • 70 Pages
  • Global
From
US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026 - Product Thumbnail Image

US Breast Cancer Drug Market, Drug Price, Dosage & Clinical Trials Insight 2026

  • Report
  • January 2021
  • 900 Pages
  • United States
From
Capecitabine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027) - Product Thumbnail Image

Capecitabine Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • Report
  • January 2022
  • 121 Pages
  • Global
From
Breast Cancer Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030 - Product Thumbnail Image

Breast Cancer Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030

  • Report
  • August 2022
  • 119 Pages
  • Global
From
Investigation Report on China's Pertuzumab Market 2021-2025 - Product Thumbnail Image

Investigation Report on China's Pertuzumab Market 2021-2025

  • Report
  • June 2021
  • 50 Pages
  • China
From
Pertuzumab Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Pertuzumab Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • August 2023
  • 96 Pages
  • Global
From
Global Breast Cancer Therapeutics Market Report and Forecast 2023-2031 - Product Thumbnail Image

Global Breast Cancer Therapeutics Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 160 Pages
  • Global
From
Global Breast Cancer Treatment Market Report and Forecast 2023-2031 - Product Thumbnail Image

Global Breast Cancer Treatment Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
  • 12 Results (Page 1 of 1)
Loading Indicator

Pertuzumab is a monoclonal antibody used in the treatment of breast cancer. It is used in combination with other drugs, such as trastuzumab and chemotherapy, to treat HER2-positive breast cancer. Pertuzumab works by blocking the HER2 receptor, which is found on the surface of some cancer cells. This prevents the cancer cells from receiving signals that promote their growth and survival. Pertuzumab is approved for use in combination with trastuzumab and chemotherapy for the treatment of HER2-positive metastatic breast cancer. It is also approved for use in combination with trastuzumab and docetaxel for the treatment of HER2-positive early-stage breast cancer. Companies in the Pertuzumab market include Roche, Merck, Pfizer, and AstraZeneca. Show Less Read more